National
Baldwin makes history with Senate victory in Wis.
Becomes first openly gay U.S. senator
Senator-elect Tammy Baldwin defeated former Wisconsin Gov. Tommy Thompson this week. (Washington Blade file photo by Michael Key)
In an historic first, lesbian Rep. Tammy Baldwin won her race for the U.S. Senate from Wisconsin Tuesday night, becoming the first openly gay person to serve in the Senate.
With 99 percent of precincts reporting Wednesday morning, Baldwin was ahead of former Wisconsin Gov. Tommy Thompson by a 51 percent to 46 percent margin.
“I am honored and humbled and grateful,” Baldwin said in election night remarks. “And I am ready to get to work, ready to stand with President Barack Obama, ready to fight for Wisconsin’s middle class!”
LGBT organizations throughout the country hailed Baldwin’s victory as an important milestone in the LGBT rights movement.
“This is a historic victory not only for the people of Wisconsin, but for lesbian, gay, bisexual and transgender Americans across the country who have finally gained an authentic and powerful voice in Congress’ upper chamber,” said Chuck Wolf, president and CEO of the Gay and Lesbian Victory Fund, which provided financial support for Baldwin’s campaign.
“Tonight Tammy shattered a glass ceiling that has existed for more than two centuries, and we could not be more thrilled,” Wolf said.
Baldwin’s supporters in Wisconsin noted that she also broke another barrier by becoming the first woman to be elected to the U.S. Senate from Wisconsin.
Chad Griffin, president of the Human Rights Campaign, which also provided financial support and field workers to assist Baldwin’s campaign, said Baldwin succeeded in drawing support from voters on a wide range of issues.
“With a relentless focus on the issues that matter to most Wisconsin voters – economic security, access to healthcare and fairness and inclusion for all,” Griffin said, “she’s earned the respect of all her constituents, gay and straight.”
As of Wednesday afternoon, the election division of the Wisconsin Government Accountability Board, which runs the state’s elections, reported that Baldwin received 1,533,868 votes, or 51 percent of the total. The board reported that Thompson received 1,370,664 votes, at 46 percent.
Two other candidates received a combined total of 3 percent of the vote, the board reported.
Early polls showed Thompson with a slight lead over Baldwin shortly after Thompson won the GOP nomination in a primary in August. By the middle of September, polls showed Baldwin in the lead, but the size of her lead narrowed by late October, with some pollsters saying the two candidates were in a statistical tie going into Tuesday’s election.
Baldwin’s quest to become the nation’s first openly gay U.S. senator captured the attention of the LGBT people across the country, many of whom contributed money to Baldwin’s campaign.
She also received backing from the Democratic Senatorial Campaign Committee and other Democratic leaning groups, including labor unions, environmental organizations and the women’s advocacy group Emily’s List.
In 1998, Baldwin became the first openly gay non-incumbent to win election to the U.S. House when she won her race for Wisconsin’s Second Congressional District in which the state capital of Madison is located.
In her seven terms in Congress, Baldwin became known as one of the strongest advocates of LGBT rights in the House as well as one of the strongest champions of progressive causes and policies.
Thompson, whose supporters describe him as a moderate, served as governor of Wisconsin between 1987 and 2001. He served as Secretary of the U.S. Department of Health and Human Services in the Bush administration from 2001 to 2005. He became a candidate for the Republican presidential nomination in 2008 but dropped out of the race before the start of the primaries.
Thompson has said he personally opposes same-sex marriage and supports the Defense of Marriage Act, which defines marriage under federal law as a union only between a man and a woman. But he has said he doesn’t favor a constitutional amendment to ban marriage equality and favors leaving same-sex marriage decisions to the states.
He has said he opposes workplace discrimination based on someone’s sexual orientation but has not said whether he would support federal legislation to ban anti-LGBT discrimination in the workplace.
Although Wisconsin members of the gay Republican group Log Cabin Republicans supported Thompson, the national Log Cabin organization, which endorsed GOP presidential candidate Mitt Romney for president, didn’t endorse Thompson.
“We endorsed candidates that engaged with us and asked for our endorsement,” said Log Cabin president R. Clarke Cooper, who noted that the group endorsed just four U.S. Senate candidates this year.
The outcome of Tuesday’s Senate election in Wisconsin marked the end of a bruising campaign, which the Milwaukee Journal Sentinel says may have broken a national record for the most negative TV ads of any U.S. Senate campaign in the state and possibly in the nation.
The Journal Sentinel reports that both Baldwin and Thompson appear to have lashed out at each other with equal force, with some independent observers saying some of the ads from both sides included misleading information.
None of the Thompson attack ads appear to have singled out Baldwin based on her sexual orientation.
However, in at least one instance, a Thompson campaign official sent an email to the news media in early September, one day before Baldwin spoke before the Democratic National Convention in Charlotte, N.C., highlighting Baldwin’s appearance at an LGBT Pride festival in Madison several years earlier.
The email, sent by Thompson campaign staffer Brian Nemoir, included an attached YouTube video showing Baldwin waiving her arms while dancing on a stage with the popular Wisconsin rock band V05. Some of the band members were dressed in Wonder Woman costumes as the band played the theme song for the Wonder Woman TV series.
Nemoir stated in his email that Baldwin was scheduled to discuss “heartland values” in her Democratic Convention speech.
“Clearly, there’s no one better positioned to talk ‘heartland values’ than Tammy,” he said sarcastically in the email.
Baldwin supporters called the email a form of gay baiting, saying it was an attempt to question Baldwin’s values because she appeared at an LGBT Pride event. A Thompson campaign spokesperson said Nemoir was acting as an individual and not on behalf of the campaign when he sent the email and video.
While the Thompson campaign’s negative TV ads steered clear of Baldwin’s sexual orientation, they sought to portray her as an ultra liberal politician out of touch with the needs of the state and the country.
One ad pointed to Baldwin’s longstanding support for a single payer health insurance system, quoting her as saying several years ago that the single payer system she supported is a “government takeover of medicine.” Another ad noted that Baldwin voted four times against economic sanctions for Iran, criticizing her judgment on a key foreign policy issue.
Baldwin responded to the health insurance attack by saying she voted for and continues to support the Affordable Care Act, President Obama’s health insurance reform measure that Congress passed two years ago. She said her support for a single payer system was “moot” since the Obama measure is about to be implemented.
She said she voted against sanctions for Iran at a time when she was hopeful that dissident groups in Iran would overturn Iran’s government and establish a true democratic system. She said she began voting for sanctions after determining that the opposition forces didn’t have the strength to change the government.
A Thompson campaign attack ad that drew expressions of outrage from Baldwin’s campaign and its supporters showed video footage of the devastation of the World Trade Center in New York following the Sept. 11, 2001 terrorist attacks and denounced Baldwin for voting against a 2006 House resolution honoring victims of the attacks.
Baldwin said she voted for at least four other 9/11 resolutions honoring victims of the terrorist attacks but voted against the 2006 resolution because it included other provisions on unrelated issues with which she disagreed.
In her own TV ads, Baldwin fired back at Thompson, citing reports by New York firefighters saying the U.S. Department of Health and Human Services, which Thompson headed at the time of the 9/11 attacks, was slow in responding to firefighters’ calls for assistance for their illnesses believed to be caused by the fumes and contaminated dust that engulfed them while responding to the World Trade Center disaster.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
How to cope when a partner gives you the silent treatment
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
